Dr. Alison Lynn Shirley, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 101 Blakenrod Blvd, Coxs Creek, KY 40013 Phone: 502-348-8338 Fax: 502-348-8114 |
News Archive
Noting "PEPFAR has been criticized for its vertical or 'stove-piping' structure, with resources targeting a specific disease rather than working to strengthen the underlying health system," a study published in the Journal of Acquired Immune Deficiency Syndromes "aimed to evaluate whether PEPFAR activities were associated with system-wide improvements in both proximal and distal indicators of health systems strengthening."
The researchers studied a mechanism of action they call the "magic spot" – an important regulator of gene expression. They describe their results in the current issue of the journal Cell.
Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.
PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.
A comprehensive, population-based strategy is needed to reduce the alarming prevalence of obesity in the United States, according to a new American Heart Association scientific statement published in Circulation: Journal of the American Heart Association.
› Verified 9 days ago